Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.485
+0.135 (5.74%)
Jan 2, 2026, 3:57 PM EST - Market open
Palisade Bio Employees
Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,403,250
Market Cap
370.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PALI News
- 3 days ago - Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 - GlobeNewsWire
- 10 days ago - Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
- 4 weeks ago - Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development - GlobeNewsWire
- 5 weeks ago - Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations - GlobeNewsWire
- 2 months ago - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
- 2 months ago - Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewsWire
- 3 months ago - Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewsWire